The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility of the Idylla CDx MSI test in identifying MSI-H mCRC patients eligible for nivolumab monotherapy or in combination with ipilimumab therapy (CheckMate 8HW phase III trial).
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Aptitude Health; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Medicenna; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Sanofi; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Biocartis
Travel, Accommodations, Expenses - Bristol-Myers Squib; Bristol-Myers Squibb; Merck; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
David Yu
Employment - Bristol-Myers Squibb
Leadership - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Chelsea Jin
Employment - Bristol-Myers Squibb
 
Lize Bollen
Employment - Biocartis
 
Bram De Craene
Employment - Biocartis
 
Wolfgang Korn
Employment - Biocartis; Invitae
Leadership - Biocartis; Invitae
Stock and Other Ownership Interests - Biocartis; Caris Life Sciences
Travel, Accommodations, Expenses - Biocartis; Invitae
 
Jim Pratt
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jonathan Baden
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb Belgium
 
Ming Lei
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Lixian Jin
Employment - Bristol-Myers Squibb
 
Elvis Cela
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Myriam Chalabi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); MSD (Inst); Roche/Genentech
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech, Therapeutics, S.L. (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim de España S.A. (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Enterome BioScience SA (Inst); Exelixis (Inst); Genentech (Inst); Gercor (Inst); GlaxoSmithKline (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); NuCana plc. (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sofie Metsu
Employment - Biocartis
 
Tiruneh Hailemariam
Employment - Biocartis
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono